Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

On the Move (Who's Going Where in Biopharma and Medtech Start-Ups (10/2009)

This article was originally published in Start Up

Executive Summary

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

You may also be interested in...



Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co.

Takeda Vaccines VP switches to cancer immunotherapy and vaccine company Bavarian Nordic and Novartis Institutes exec moves to molecular medicines firm Boston Pharmaceuticals, each in the CMO position. Meanwhile, Merck & Co will add a scientific and a strategic expert to its board.

 

Executives On The Move: Bayer Names Upcoming Information Chief And Legal Hires At Eli Lilly And CytoDyn

Stryker tech officer will become Bayer AG’s chief information technology and digital transformation Officer in June. In addition, monoclonal antibody therapy firm CytoDyn and global pharma Eli Lilly each hire a general counsel.

Executives On The Move: Gamida Cell Decides On Regulatory Appointment, Twist Bio Announces A Promotion And A VP Leaves Sanofi Genzyme For Krystal Biotech

Cellular and immune therapeutics company Gamida Cell has a new chief regulatory and quality officer and the SVP, R&D at Twist Biosciences steps higher to the chief operating officer position. At Sanofi Genzyme a genetic diseases VP leaves to become chief commercial officer at Krystal Biotech.

UsernamePublicRestriction

Register

SC091865

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel